Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Pfizer to launch new products under Corex brand

At the same time, the company will discontinue the production of the current Corex cough syrup formulation (a combination of codeine phosphate and chlorpheniramine maleate)

Rakesh Rao  |  Mumbai 

Pfizer to acquire oncology specialist Medivation for $ 14 bn

Ltd has decided to launch a series of products as line extensions under the brand name, starting with the first launch in December 2016 and subsequent launches over the next year. At the same time, the company will discontinue the production of the current formulation (a combination of codeine phosphate and chlorpheniramine maleate) in the country. had recorded a sale of Rs 244.48 crores for the financial year ended March 31, 2016.

stands by the safety and efficacy of its current formulation that has been duly approved by central and state regulators. As with this formulation, all additional line extensions will be introduced with all due regulatory approvals in place,” said the company in a BSE filing today.

The decision was taken after undertook a comprehensive review of its respiratory offerings in order to better cover a broader range of indications through an expanded product portfolio. As a result of this review, the company decided to launch additional products while discontinuing the manufacture of certain SKUs.

“The company remains committed to providing a more comprehensive set of solutions in respiratory indications, while ensuring minimal impact towards patients resulting from the discontinuation of manufacturing of the current formulation,” added Pfizer.

RECOMMENDED FOR YOU

Pfizer to launch new products under Corex brand

At the same time, the company will discontinue the production of the current Corex cough syrup formulation (a combination of codeine phosphate and chlorpheniramine maleate)

At the same time, the company will discontinue the production of the current Corex cough syrup formulation (a combination of codeine phosphate and chlorpheniramine maleate)
Ltd has decided to launch a series of products as line extensions under the brand name, starting with the first launch in December 2016 and subsequent launches over the next year. At the same time, the company will discontinue the production of the current formulation (a combination of codeine phosphate and chlorpheniramine maleate) in the country. had recorded a sale of Rs 244.48 crores for the financial year ended March 31, 2016.

stands by the safety and efficacy of its current formulation that has been duly approved by central and state regulators. As with this formulation, all additional line extensions will be introduced with all due regulatory approvals in place,” said the company in a BSE filing today.

The decision was taken after undertook a comprehensive review of its respiratory offerings in order to better cover a broader range of indications through an expanded product portfolio. As a result of this review, the company decided to launch additional products while discontinuing the manufacture of certain SKUs.

“The company remains committed to providing a more comprehensive set of solutions in respiratory indications, while ensuring minimal impact towards patients resulting from the discontinuation of manufacturing of the current formulation,” added Pfizer.
image
Business Standard
177 22

Pfizer to launch new products under Corex brand

At the same time, the company will discontinue the production of the current Corex cough syrup formulation (a combination of codeine phosphate and chlorpheniramine maleate)

Ltd has decided to launch a series of products as line extensions under the brand name, starting with the first launch in December 2016 and subsequent launches over the next year. At the same time, the company will discontinue the production of the current formulation (a combination of codeine phosphate and chlorpheniramine maleate) in the country. had recorded a sale of Rs 244.48 crores for the financial year ended March 31, 2016.

stands by the safety and efficacy of its current formulation that has been duly approved by central and state regulators. As with this formulation, all additional line extensions will be introduced with all due regulatory approvals in place,” said the company in a BSE filing today.

The decision was taken after undertook a comprehensive review of its respiratory offerings in order to better cover a broader range of indications through an expanded product portfolio. As a result of this review, the company decided to launch additional products while discontinuing the manufacture of certain SKUs.

“The company remains committed to providing a more comprehensive set of solutions in respiratory indications, while ensuring minimal impact towards patients resulting from the discontinuation of manufacturing of the current formulation,” added Pfizer.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard